WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...

A Chinese pharmaceutical company expects to hire up to 500 employees for the first phase of its new campus in northern ...

WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025, the deal ...

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing ...

We cut our fair value estimate on narrow-moat-rated WuXi Biologics to HKD 24.60 per share from HKD 28.10 as we lower our project growth assumption for the next decade. We take a fresh look after ...

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation ...

The employees at WuXi Biologics have once again shown their commitment to the local community with their fourth annual ...

We are excited to further the advances made by WuXi Biologics and to unlock the full potential of this molecule,” said Dr. Ken Song, Chairman, President and CEO of Candid. Dr. Chris Chen ...

SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing ...